Search company, investor...

Ribozyme Pharmaceuticals


Other Investors | Alive

About Ribozyme Pharmaceuticals

Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease

Headquarters Location

80 Blue Ravine Road Suite 100 Folsom

Folsom, California, 95630,

United States


Missing: Ribozyme Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ribozyme Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Ribozyme Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ribozyme Pharmaceuticals Rank

Ribozyme Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Ribozyme Pharmaceuticals's headquarters?

    Ribozyme Pharmaceuticals's headquarters is located at 80 Blue Ravine Road, Folsom.

  • What is Ribozyme Pharmaceuticals's latest funding round?

    Ribozyme Pharmaceuticals's latest funding round is Other Investors.

  • Who are the investors of Ribozyme Pharmaceuticals?

    Investors of Ribozyme Pharmaceuticals include Morgenthaler Ventures.

  • Who are Ribozyme Pharmaceuticals's competitors?

    Competitors of Ribozyme Pharmaceuticals include Cevec Pharmaceuticals, Selexys Pharmaceuticals, Novus Therapeutics, Azevan Pharmaceuticals, Elixir Pharmaceuticals and 16 more.

Compare Ribozyme Pharmaceuticals to Competitors

Bluefish Pharmaceuticals

Bluefish Pharmaceuticals offers a range of quality pharmaceuticals at prices that as many as possible will be able to afford.

Alinea Pharmaceuticals

Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders

Greystone Pharmaceuticals

Greystone Pharmaceuticals is a healthcare company focused on wound technologies.

NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Ausio Pharmaceuticals

Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.


Recodgen is developing therapeutics targeting genetic expressions to disease

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.